Long-acting contraceptives in adolescents

Current Opinion in Obstetrics and Gynecology

Volumn 19, Issue 5, 2007, Pages 453-460

  Tolaymat, Lama L ^a   Kaunitz, Andrew M ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Adolescents; Contraception; Contraceptive implants; Depot medroxyprogesterone acetate

Indexed keywords

COPPER INTRAUTERINE DEVICE; ETONOGESTREL; GESTAGEN; INJECTABLE CONTRACEPTIVE AGENT; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT;

ADOLESCENT; ADOLESCENT PREGNANCY; BIRTH CONTROL; BODY WEIGHT; BONE DENSITY; CONDOM; CONTRACEPTION; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ORGANIZATION; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; LACTATION; MENSTRUAL CYCLE; MOOD CHANGE; PRIORITY JOURNAL; PUERPERIUM; REVIEW; SEXUALLY TRANSMITTED DISEASE; SIDE EFFECT; SKELETON;

ADMINISTRATION, ORAL; ADOLESCENT; ADOLESCENT MEDICINE; CONTRACEPTIVE AGENTS, FEMALE; DELAYED-ACTION PREPARATIONS; DESOGESTREL; FEMALE; GYNECOLOGY; HUMANS; INTRAUTERINE DEVICES; MEDROXYPROGESTERONE 17-ACETATE; PATIENT COMPLIANCE; PREGNANCY; PREGNANCY IN ADOLESCENCE; UNITED STATES;

EID: 34648847324     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/GCO.0b013e3282ef1cd2     Document Type: Review

References (80)

1. Santelli JS, Lindberg LD, Finer LB, Singh S. Explaining recent declines in adolescent pregnancy in the United States: the contribution of abstinence and improved contraceptive use. Am J Public Health 2007; 97:150-157.
2. Westhoff C. Depot-medroxyprogesterone acetate injection (Depo-Provera): a highly effective contraceptive option with proven long-term safety. Contraception 2003; 68:75-87.
3. Bernstein N. Young love, new caution - first of two articles. Behind fall in pregnancy, a new teenage culture of restraint. New York Times 7 March 2004.
4. Kaunitz AM. Long-acting hormonal contraceptives - indispensable in preventing teen pregnancy. J Adolesc Health 2007; 40:1-3.
5. Trussell J. Contraceptive failure in the United States. Contraception 2004; 70:89-96.
6. Dinerman LM, Wilson MD, Duggan AK, Joffe A. Outcomes of adolescents using levonorgestrel implants vs oral contraceptives or other contraceptive methods. Arch Pediatr Adolesc Med 1995; 149:967-972.
7. Templeman CL, Cook V, Goldsmith LJ, et al. Postpartum contraceptive use among adolescent mothers. Obstet Gynecol 2000; 95:770-776.
8. O'Dell C, Forke C, Polaneczky M, et al. Depo-Provera vs. oral contraceptive use by postpartum adolescents [Abstract]. J Adolesc Health 1997; 20:127.
9. Stevens-Simon C, Kelly L, Kulick R. A village would be nice but. . . it takes a long-acting contraceptive to prevent repeat adolescent pregnancies. Am J Prev Med 2001; 21:60-65.
10. Abma JC, Martinez GM, Mosher WD, Dawson BS. Teenagers in the United States: sexual activity, contraceptive use, and childbearing, 2002 (Vital and Health Statistics) Series 23, No. 24, Hyattsville, MD: National Center for Health Statistics. 2005; 54 pp.
11. Ranjit N, Bankole A, Darroch JE, Singh S. Contraceptive failure in the first 2 years of use: differences across socioeconomic subgroups. Fam Plann Perspect 2001; 33:19-27.
12. Sneed R, Westhoff C, Monroni C, Tiezzi L. A prospective study of immediate initiation of depo medroxyprogesterone acetate contraceptive injection. Contraception 2005; 71:99-103.
13. Balkus J, Miller L. Same-day administration of depot-medroxyprogesterone acetate injection: a retrospective review. Contraception 2005; 71:395-398.
14. Rickert VI, Tiezzi L, León J, et al. Depo now: preventing unintended pregnancies among adolescents. J Adolesc Health 2007; 40:22-28.
15. Nelson AL, Katz T. Initiation and continuation rates seen in 2-year experience with same day injections of DMPA. Contraception 2007; 75:84-87.
16. Borgatta L, Murthy A, Chuang C, et al. Pregnancies diagnosed during Depo-Provera use. Contraception 2002; 66:169-172.
17. Schwallie PC, Assenzo JR. The effect of depot medroxyprogesterone acetate on pituitary and ovarian function, and the return of fertility following its discontinuation: a review. Contraception 1974; 10:181-202.
18. Leiman G. Depo-medroxyprogesterone acetate as a contraceptive agent: its effect on weight and blood pressure. Am J Obstet Gynecol 1972; 114:97-102.
19. Sapire KE. Letter to the Editor: Depo-Provera and carbamazepine. Br J Fam Plann 1990; 15:130.
20. Belsey EM. Vaginal bleeding patterns among women using one natural and eight hormonal methods of contraception. Contraception 1988; 38:181-206.
21. Schlaff WD, Carson SA, Luciano A, et al. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertil Steril 2006; 85:314-325.
22. Muse K. Hormonal manipulation in the treatment of premenstrual syndrome. Clin Obstet Gynecol 1992; 35:658-666.
23. Johnson SR. Premenstrual syndrome, premenstrual dysphoric disorder, and beyond: a clinical primer for practitioners. Obstet Gynecol 2004; 104:845-859.
24. Mattson RH, Cramer TA, Caldwell BV, et al. Treatment of seizures with medroxyprogesterone acetate: preliminary report. Neurology 1984; 34:1255-1258.
25. De Ceulaer K, Gruber C, Hayes R, Serjeant GR. Medroxyprogesterone acetate and homozygous sickle-cell disease. Lancet 1982; ii:229-231.
26. Thomas DB, Ray RM. Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Cancer 1991; 49:186-190.
27. Skegg DC, Noonan EA, Paul C, et al. Depot medroxyprogesterone acetate and breast cancer. JAMA 1994; 273:779-804.
28. Mishell DR Jr. Pharmacokinetics of depot medroxyprogesterone acetate contraception. J Reprod Med 1996; 41:381-390.
29. Clark MK, Sowers M, Levy BT, Tenhundfeld P. Magnitude and variability of sequential estradiol and progesterone concentrations in women using depot medroxyprogesterone acetate for contraception. Fertil Steril 2001; 75:871-877.
30. Gbolade BA. Depo-Provera and bone density. J Fam Plann Reprod Healthcare 2002; 28:7-11.
31. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995; 332:767-773.
32. McClung MR. The relationship between bone mineral density and fracture risk. Curr Osteoporos Rep 2005; 3:57-63.
33. Grimes DA, Schulz KF. Surrogate end points in clinical research: hazardous to your health. Obstet Gynecol 2005; 105:1114-1118.
34. Cefalu CA. Is bone mineral density predictive of fracture risk reduction? Curr Med Res Opin 2004; 20:341-349.
35. Curtis KM, Martins SL. Progestogen-only contraception and bone mineral density: a systematic review. Contraception 2006; 73:470-487.
36. Kaunitz AM. Beyond the pill: new data and options in hormonal and intrauterine contraception. Am J Obstet Gynecol 2005; 192:998-1004.
37. Scholes D, Lacroix AZ, Ichikawa LE, et al. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch Pediatr Adolesc Med 2005; 159:139-144.
38. Kalkwarf HJ. Lactation and maternal bone health. Adv Exp Med Biol 2004; 554:101-114.
39. Polatti F, Capuzzo E, Viazzo F, et al. Bone mineral changes during and after lactation. Obstet Gynecol 1999; 94:52-56.
40. Hayslip CC, Klein TA, Wray HL, Duncan WE. The effects of lactation on bone mineral content in healthy postpartum women. Obstet Gynecol 1989; 73:588-592.
41. Kalkwarf HJ, Specker BL. Bone mineral loss during lactation and recovery after weaning. Obstet Gynecol 1995; 86:26-32.
42. Karlsson C, Obrant KJ, Karlsson M. Pregnancy and lactation confer reversible bone loss in humans. Osteoporos Int 2001; 12:828-834.
43. Chantry CJ, Auinger P, Byrd RS. Lactation among adolescent mothers and subsequent bone mineral density. Arch Pediatr Adolesc Med 2004; 158:650-656.
44. Honda A, Kurabayashi T, Yahata T, et al. Lumbar bone mineral density changes during pregnancy and lactation. Int J Gynaecol Obstet 1998; 63:253-325.
45. Michaelsson K, Baron JA, Farahmand BY, Ljunghall S. Influence of parity and lactation on hip fracture risk. Am J Epidemiol 2001; 153:1166-1172.
46. World Health Organization. WHO Statement on Hormonal Contraception and Bone Health. Geneva: World Health Organization 2005: 1-2.
47. Cromer BA, Scholes D, Berenson A, et al. Depot medroxyprogesterone acetate and bone mineral density in adolescents - the black box warning: a position paper of the Society for Adolescent Medicine. J Adolesc Health 2006; 39:296-301. This paper reviewed the black box warning regarding DMPA and bone loss as it relates to adolescent girls. Issues that are discussed include the low risk of fracture related to DMPA use, evidence of recovery after discontinuation of DMPA, and the need to balance the benefits of this highly effective contraceptive with theoretical concerns regarding its impact on bone health.
48. Black A. Canadian contraception consensus - update on depot medroxyprogesterone acetate (DMPA). J Obstet Gynaecol Can 2006; 28:305-313.
49. American College of Obstetricians and Gynecologists. Use of hormonal contraception in women with coexisting medical conditions. ACOG Practice Bulletin Number 73, June 2006. Obstet Gynecol 2006; 107: 1453-1472. This bulletin provides extensive information to help clinicians appropriately advise their patients with medical concerns regarding the use of hormonal contraception.
50. Gray RH, Campbell OM, Zacur HA, et al. Postpartum return of ovarian activity in nonbreastfeeding women monitored by urinary assays. J Clin Endocrinol Metab 1987; 64:645-650.
51. Speroff L, Darney P. A clinical guide for contraception. 4th ed. Baltimore: Williams and Wilkins; 2005.
52. Halderman LD, Nelson AL. Impact of early postpartum administration of progestin-only hormonal contraceptives compared with nonhormonal contraceptives on short-term breast-feeding patterns. Am J Obstet Gynecol 2002; 186:1250-1256; discussion 1256-1258.
53. Koetsawang S. The effects of contraceptive methods on the quality and quantity of breast milk. Int J Gynaecol Obstet 1987; 25 (Suppl):115-127.
54. Guiloff E, Ibarra-Polo A, Zanartu J, et al. Effect of contraception on lactation. Am J Obstet Gynecol 1974; 118:42-45.
55. Karim M, Ammar R, El Mahgoub S, et al. Injected progestogen and lactation. BMJ 1971; 1:200-203.
56. Bonny A, Camlin K, Harvey R, et al. Prospective analysis of weight changes in adolescent females initiating depot medroxyprogesterone acetate (DMPA), oral contraceptive pills (OC), or no hormonal contraceptive method. J Adolesc Health 2003; 32:134.
57. Harel Z, Biro FM, Kollar LM. Adolescents' reasons for and experience after discontinuation of the long-acting contraceptives Depo-Provera and Norplant. J Adolesc Health 1996; 19:118-123.
58. Moore L, Valuck R, McDougall C, et al. A comparative study of one year weight gain among users of medroxyprogesterone acetate, levonorgestrel implants, and oral contraceptives. Contraception 1995; 52:215-219.
59. Bonny A, Ziegler J, Harvey R. Relationship between baseline obesity status and subsequent weight gain in adolescent females initiating depot medroxyprogesterone acetate (DMPA), oral contraceptive pills (OC), or no hormonal contraceptive method. Pediatr Res 2004; 55:9A.
60. Pelkman CL, Chow M, Heinbach R, Rolls BJ. Short-term effects of a progestational contraceptive drug on food intake, resting energy expenditure, and body weight in young women. Am J Clin Nutr 2001; 73:19-26.
61. Westhoff C, Truman C, Kalmuss D, et al. Depressive symptoms and Depo-Provera. Contraception 1998; 57:237-240.
62. Gupta N, O'Brien R, Jacobsen LJ, et al. Mood changes in adolescents using depot-medroxyprogesterone acetate for contraception: a prospective study. J Pediatr Adolesc Gynecol 2001; 14:71-76.
63. Glasier A. Implantable contraceptives for women: effectiveness, discontinuation rates, return of fertility, and outcome of pregnancies. Contraception 2002; 65:29-37.
64. Funk S, Miller MM, Mishell DR Jr, et al. Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel. Contraception 2005; 71:319-326.
65. Makarainen L, Van Beek A, Tuomivaara L, et al. Ovarian function during the use of a single contraceptive implant: Implanon compared with Norplant. Fertil Steril 1998; 69:714-721.
66. Beerthuizen R, Van Beek A, Massai R, et al. Bone mineral density during long-term use of the progestagen contraceptive implant Implanon compared to a nonhormonal method of contraception. Hum Reprod 2000; 15:118-122.
67. Reinprayoon D, Taneepanichskul S, Bunyavejchevin S, et al. Effects of the etonogestrel-releasing contraceptive implant (Implanon, on parameters of breastfeeding compared to those of an intrauterine device. Contraception 2000; 62:239-246.
68. Patai K, Szilagyi G, Noszal B, Szentmariay I. Local tissue effects of copper-containing intrauterine devices. Fertil Steril 2003; 80:1281.
69. Alvarez F, Brache V, Fernandez E, et al. New insights on the mode of action of intrauterine contraceptive devices in women. Fertil Steril 1988; 49:768-773.
70. Peterson HB, Curtis KM. Clinical practice. Long-acting methods of contraception. N Engl J Med 2005; 353:2169-2175.
71. Rivera R, Chen-Mok M, McMullen S. Analysis of client characteristics that may affect early discontinuation of the TCu-380A IUD. Contraception 1999; 60:155-160.
72. Nilsson CG, Lahteenmaki PL, Luukkainen T. Ovarian function in amenorrheic and menstruating users of a levonorgestrel-releasing intrauterine device. Fertil Steril 1984; 41:52-55.
73. Andersson JK, Rybo G. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br J Obstet Gynaecol 1990; 97:690-694.
74. Petta CA, Ferriani RA, Abrao MS, et al. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. Hum Reprod 2005; 20:1993-1998; Epub 24 March 2005.
75. Hubacher D, Lara-Ricalde R, Taylor DJ, et al. Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. N Engl J Med 2001; 345:561-567.
76. Diaz J, Pinto Neto AM, Bahamondes L, et al. Performance of the copper T 200 in parous adolescents: are copper IUDs suitable for these women? Contraception 1993; 48:23-28.
77. Zhang J, Feldblum PJ, Chi IC, Farr MG. Risk factors for copper T IUD expulsion: an epidemiologic analysis. Contraception 1992; 46:427-433.
78. Hubacher D, Goco N, Gonzalez B, Taylor D. Factors affecting continuation rates of DMPA. Contraception 2000; 60:345-351.
79. Grimes D, Schulz K, Stanwood N. Immediate postabortal insertion of intrauterine devices. Cochrane Database Syst Rev 2000; 2:CD001777.
80. ParaGard T380A intrauterine copper contraceptive. Patient package. Duramed Pharmaceuticals, Inc., subsidiary of Barr Pharmaceuticals, Inc. Pomona, New York, 2006.